Vicarious Surgical Analyst Ratings
Morgan Stanley Cuts Price Target on Vicarious Surgical to $10 From $18, Keeps Equalweight Rating
Vicarious Surgical (RBOT) Gets a Hold From Piper Sandler
Buy Rating Affirmed: Vicarious Surgical's Advancements Poised to Disrupt Medical Robotics
A New Cause for Concern: Vicarious Surgical Inc. Adds a New Share Price & Shareholder Rights Risk
Vicarious Surgical Analyst Ratings
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Vicarious Surgical (RBOT) and 89bio (ETNB)
BTIG Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
BTIG Sticks to Their Hold Rating for Vicarious Surgical (RBOT)
Morgan Stanley Initiates Coverage On Vicarious Surgical With Equal-Weight Rating, Announces Price Target of $0.6
Vicarious Surgical Analyst Ratings
Canaccord Cuts Vicarious Surgical to Hold, Cites Timelines Delays
Analysts Offer Insights on Healthcare Companies: Vicarious Surgical (RBOT) and Evogene (EVGN)
Piper Sandler Keeps Their Hold Rating on Vicarious Surgical (RBOT)
Canaccord Genuity Downgrades Vicarious Surgical to Hold, Lowers Price Target to $0.4
Vicarious Surgical Analyst Ratings
BTIG Downgrades Vicarious Surgical (RBOT) to a Hold
BTIG Reaffirms Their Buy Rating on Vicarious Surgical (RBOT)
Vicarious Surgical (RBOT) Receives a Hold From Piper Sandler
Piper Sandler Remains a Hold on Vicarious Surgical (RBOT)